Pharma BD Deal Intelligence
The $6.9B acquisition that hid the most valuable molecule in pharmaceutical history inside a BASF chemicals divestiture. D2E7, buried in Knoll's portfolio, became Humira—generating $200B+ in cumulative revenue and peak sales exceeding $20B/year.
Greatest ROI in pharma history: $6.9B purchase yielded $231B in Humira revenue
Full analysis, sources & comparables →Abbott to buy Knoll for $6.9 billion, acquiring BASF's pharmaceutical business including the promising monoclonal antibody D2E7.
Abbott Laboratories SEC filing related to the definitive agreement to acquire the pharmaceutical business of BASF (Knoll).
Abbott acquired adalimumab (D2E7, later branded Humira) when it purchased Knoll Pharmaceuticals from BASF in 2001 for $6.9 billion, gaining what would become…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Abbott Laboratories acquired the global pharmaceutical operations of BASF (Knoll Pharmaceuticals) for $6.9 billion in cash. The deal included D2E7, a developmental monoclonal antibody later known as Humira (adalimumab), which became the world's best-selling drug with peak annual sales exceeding $20 billion.
1.3M US cases/yr · $4.0B Global RA Market (2001)
Rheumatoid arthritis is a chronic autoimmune disease affecting approximately 1.3 million US adults, causing symmetric inflammatory polyarthritis, progressive joint destruction, and systemic manifestations. Women are 2-3 times more frequently affected than men, and risk rises with age, family history, and smoking. TNF-alpha is a central inflammatory cytokine driving synovial inflammation and bone erosion, making it a pivotal target for disease-modifying biologic therapy alongside conventional DMARDs such as methotrexate.
Abbott's $6.9B acquisition of Knoll Pharmaceuticals primarily targeted D2E7, a fully human anti-TNF antibody that became Humira -- the best-selling drug in pharmaceutical history with $21.2B peak annual sales. The deal also included Synthroid (levothyroxine), the most prescribed thyroid medication in the US.
Abbott Laboratories closes asset purchase of Knoll Pharmaceuticals (BASF Pharma) for $6.9B, establishing strategic position and initiating integration.
Abbott acquired Knoll/BASF Pharma for $6.9B, gaining Humira which became the best-selling drug ever with $231B cumulative sales.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) (this deal) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2000 deals · Abbott Laboratories deals · Cardiovascular deals